Gilead Stock Hits New 52-Week High (GILD)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Gilead (Nasdaq: GILD) hit a new 52-week high Friday as it is currently trading at $67.72, above its previous 52-week high of $67.55 with 4.9 million shares traded as of 1:50 p.m. ET. Average volume has been 6.2 million shares over the past 30 days.

Gilead has a market cap of $50.85 billion and is part of the health care sector and drugs industry. Shares are up 64.2% year to date as of the close of trading on Thursday.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. The company has a P/E ratio of 20.4, above the average drugs industry P/E ratio of 20.2 and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Gilead Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside